RedP,

You are talking about a drug here that plays big time with one's immune system. It prevents certain parts of one's immune cells from crossing the blood-brain barrier and doing what they normally do.

Now, for whatever reason, the patient has to stop taking Tysabri because the nasty side-effects can become life threatening. Now these immune system cells, after being prevented from doing their thing for a long period of time, start to go into the brain again. In reported cases, some patients are getting a huge increase in the number of brain lesions! All the MS drug trials hang their claim to fame that they reduce the number of these lesions. Now the drug they can't take anymore could possibly cause their MS to speed up tremendously.

First it was stopping the drug resulting a large increase in lesions, then it was problems with melanoma and moles and now it's possible severe liver damage happening very quickly. Do you not think that Biogen may have rushed this drug out the door a bit too quickly??!!

Here is a company (Biogen/Elan) that along with the FDA, rushed the approval process by one year. They combined it with Avonex in a trial BEFORE the drug was approved on its own. They published a part of their marketing plan on the internet, stating how many $ billions they would make and how huge a chunk of the MS drug market they would gain BEFORE the drug got approved. I just can't trust these people to be telling us what else they don't want us to know about Tysabri.

Harry